Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis.
Induction treatment of mild-to-moderate Crohn's disease is controversial.



To compare the induction of remission between different doses of mesalamine, sulfasalazine, corticosteroids, and budesonide for active Crohn's disease.



We identified randomized controlled trials from existing Cochrane reviews and an updated literature search in Medline, EMBASE, and CENTRAL to November 2015.



We included randomized controlled trials (n = 22) in adult patients with Crohn's disease that compared budesonide, sulfasalazine, mesalamine, or corticosteroids with placebo or each other, for the induction of remission (8-17 wks). Mesalamine (above and below 2.4 g/d) and budesonide (above and below 6 mg/d) were stratified into low and high doses.



Our primary outcome was remission, defined as a Crohn's Disease Activity Index score <150. A Bayesian random-effects network meta-analysis was performed on the proportion in remission.



Corticosteroids (odds ratio [OR] = 3.80; 95% credible interval [CrI]: 2.48-5.66), high-dose budesonide (OR = 2.96; 95% CrI: 2.06-4.30), and high-dose mesalamine (OR = 2.29; 95% CrI: 1.58-3.33) were superior to placebo. Corticosteroids were similar to high-dose budesonide (OR = 1.21; 95% CrI: 0.84-1.76), but more effective than high-dose mesalamine (OR = 1.83; 95% CrI: 1.16-2.88). Sulfasalazine was not significantly superior to any therapy including placebo.



Randomized controlled trials that use a strict definition of induction of remission and disease severity at enrollment to assess effectiveness in treating mild-to-moderate Crohn's disease are limited.



Corticosteroids and high-dose budesonide were effective treatments for inducing remission in mild-to-moderate Crohn's disease. High-dose mesalamine is an option among patients preferring to avoid steroids.
Departments of *Medicine and Community Health Sciences, †Community Health Sciences, and ‡Medicine, University of Calgary, Calgary, Alberta, Canada; and §Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
Stephanie
S
Coward
M Ellen
ME
Kuenzig
Glen
G
Hazlewood
Fiona
F
Clement
Kerry
K
McBrien
Rebecca
R
Holmes
Remo
R
Panaccione
Subrata
S
Ghosh
Cynthia H
CH
Seow
Ali
A
Rezaie
Gilaad G
GG
Kaplan
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001499:Bayes Theorem; D019819:Budesonide / Q000627:therapeutic use*; D057186:Comparative Effectiveness Research; D003424:Crohn Disease / Q000188:drug therapy*; D006801:Humans; D060828:Induction Chemotherapy / Q000379:methods; D019804:Mesalamine / Q000627:therapeutic use*; D016017:Odds Ratio; D016032:Randomized Controlled Trials as Topic; D012460:Sulfasalazine / Q000627:therapeutic use*; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D012460:Sulfasalazine; D019804:Mesalamine; D019819:Budesonide